NWBO - Northwest Biotherapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3470
+0.0020 (+0.58%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3450
Open0.3550
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3350 - 0.3650
52 Week Range0.1400 - 0.4200
Volume4,027,558
Avg. Volume2,147,735
Market Cap229.022M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0360
Earnings DateAug 07, 2020 - Aug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting
    PR Newswire

    NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting

    Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers, will discuss the projected schedule for reaching data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer at the Company's 2019 Annual Meeting. The Meeting is being held virtually due to the current public health crisis.

  • NW Bio Announces Annual Shareholders' Meeting Scheduled for April 18, 2020
    PR Newswire

    NW Bio Announces Annual Shareholders' Meeting Scheduled for April 18, 2020

    Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder's Meeting will be held on April 18, 2020, at 1:00 pm in Washington, DC.

  • Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team
    PR Newswire

    Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team

    Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further expanded its senior management team with the addition of Ms. Jean M. Davis as Chief Financial Officer, Chief Accounting Officer, and interim Chief Information Officer.

  • Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit
    PR Newswire

    Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit

    Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, is presenting at 11:40 a.m. today at the inaugural Glioblastoma (GBM) Drug Development Summit being held at the Westin Boston Waterfront Hotel in Boston, Massachusetts.

  • NW Bio Moves Forward With SEC Settlement
    PR Newswire

    NW Bio Moves Forward With SEC Settlement

    BETHESDA, Md., Oct. 10, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC. As previously reported, the Company has been investigated by the SEC and has cooperated with the investigation. The Company has now successfully entered into a settlement agreement with the SEC under Rule 13a-15.

  • NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations
    PR Newswire

    NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations

    BETHESDA, Md., Sept. 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has expanded its senior management team with the addition of Dr. Kevin T. Duffy as Vice President, Medical Affairs and External Collaborations. Dr. Duffy also served as Scientific Affairs Strategy and Training Lead in Merck's Global Center for Scientific Affairs for Merck's immuno-oncology franchise for hematologic malignancies.  Dr. Duffy was the recipient of numerous achievement awards during his tenure at Merck.

  • Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO
    PR Newswire

    Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO

    BETHESDA, Md., June 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today highlights from Dr. Marnix Bosch's Program Update in the Industry Expert Theater presentation at the 55th annual ASCO Conference, which was publicly webcast and was posted on the home page of the Company's website at www.nwbio.com. Dr. Bosch provided an update about the Company's DCVax®-Direct Program for inoperable tumors, including new follow-up data about patient survival in the Phase I trial and new information about the next DCVax-Direct clinical trials for new disease applications. Dr. Bosch also provided an update about the Company's DCVax®-L Program for operable tumors, including the Company's progress on the road to unblinding the data from the Phase III trial in Glioblastoma, and new follow-up data from the Information Arm of patients who were not eligible for the Phase III trial because they had actual or apparent rapid tumor progression (recurrence) before they could even be enrolled in the trial.

  • NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO
    PR Newswire

    NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO

    BETHESDA, Md., May 30, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Industry Expert Showcase Theater in the exhibit hall at the 55th Annual ASCO Convention at the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will deliver a webcast update on the Company's clinical programs. ASCO is the largest annual gathering of medical professionals in oncology, held every year at the beginning of June in Chicago.